Protein S100 Beta as a Predictor of Resuscitation Outcome

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Dr Sharon Einav, Shaare Zedek Medical Center
ClinicalTrials.gov Identifier:
NCT00814814
First received: December 24, 2008
Last updated: May 30, 2015
Last verified: May 2015

December 24, 2008
May 30, 2015
August 2008
March 2017   (final data collection date for primary outcome measure)
Poor versus good patient outcome at discharge was used to test the study hypotheses of improved prediction attributable to S100B and NSE concentration. [ Time Frame: within 24 hours of discharge ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00814814 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Protein S100 Beta as a Predictor of Resuscitation Outcome
Protein S100 Beta as a Predictor of the Outcome of Cardiopulmonary Resuscitation

Management of cardiac arrest is complicated by the lack of a readily available tool identifying individuals who are likely to be successfully resuscitated. S100 beta is a protein that originates in the astroglial cells of the brain, and NSE (Neuron Specific Enolase) is another protein that originates in the neurons themselves. In the laboratory, the concentration of these proteins correlate with evidence of brain damage after head trauma, stroke and exposure to low levels of oxygen. The concentration of these proteins in the blood of human survivors of cardiopulmonary resuscitation in humans is much higher than in patients who were resuscitated but did not survive. However, it is still unclear whether survivors from cardiopulmonary resuscitation have higher levels of these proteins in their blood if they survive with neurological injury secondary to the arrest and resuscitation.

Hypothesis: In humans, the blood concentrations of protein S100 beta and NSE during and after resuscitation can predict who will die despite cardiopulmonary resuscitation and who will survive with neurological injury secondary to the arrest and resuscitation.

Not Provided
Observational
Observational Model: Cohort
Not Provided
Retention:   Samples With DNA
Description:

Blood

Probability Sample

All victims of non-traumatic out-of hospital cardiopulmonary arrest (defined as the absence of either spontaneous respiration or palpable pulse or both) within the Jerusalem district.

Cardiopulmonary Arrest Outcome
Not Provided
Cardiopulmonary arrest
Einav S, Kaufman N, Algur N, Kark JD. Modeling serum biomarkers S100 beta and neuron-specific enolase as predictors of outcome after out-of-hospital cardiac arrest: an aid to clinical decision making. J Am Coll Cardiol. 2012 Jul 24;60(4):304-11. doi: 10.1016/j.jacc.2012.04.020.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
313
September 2018
March 2017   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • All victims of non-traumatic out-of hospital cardiopulmonary arrest (defined as the absence of either spontaneous respiration or palpable pulse or both) within the Jerusalem district.

Exclusion Criteria:

  • Patients with do-not-resuscitate orders or an advance directive to that effect.
  • Patients with intracranial hemorrhage
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Israel
 
NCT00814814
14-01-05 A and B (correction)
No
Dr Sharon Einav, Shaare Zedek Medical Center
Shaare Zedek Medical Center
Not Provided
Principal Investigator: Sharon Einav, MD Shaare Zedek Medical Center
Shaare Zedek Medical Center
May 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP